Ebos profit falls but dividend holds steady as Chemist Warehouse era ends

Ebos profit falls but dividend holds steady as Chemist Warehouse era ends
Ebos has invested about $360m in new facilities including room to store the increasingly popular weight loss drugs such as Wegovy. (Image: Getty)
Rebecca Stevenson
Ebos’ profit has fallen, but it will pay investors the same dividend as it moves on without the Chemist Warehouse contract. For the year to June 30, the health and animal care group reported revenue of A$12.3 billion (NZ$13.6b) and underlying earnings of A$585 million. Its guidance was for underlying earnings before interest, taxation, depreciation and amortisation (ebitda) of between A$575m and A$600m. Revenue dropped 7.0% compared to the previous financial year.  It lost the $1.9b Chemist Warehouse contract in 2023....

More Markets

NZ sharemarket up 0.3% despite business confidence drop
Markets Market Close

NZ sharemarket up 0.3% despite business confidence drop

The S&P/NZX 50 Index closed at 13,531.29, up 42.05 points or 0.31%.

ASB settles CCCFA class action for hefty $135.6m
Finance

ASB settles CCCFA class action for hefty $135.6m

 It ended a four-year class action centred on disclosure obligations.

ASB pays $135.6m to settle long-running CCCFA class action
Finance

ASB pays $135.6m to settle long-running CCCFA class action

High-street lender ASB has agreed to pay $135.6 million to settle a class action brought against it for alleged breaches of the Credit Contracts and Consumer Finance Act (CCCFA).The settlement – without admission of liability or wrongdoing – concluded four years of legal proceedi...